Revolution Medicines Inc expected to post a loss of $1.98 a share - Earnings Preview

Revolution Medicines

04/08/2026 24:55

Revolution Medicines Inc RVMD.OQ RVMD.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Redwood City California-based  company is expected to report revenue of $16.375 million, according to the mean estimate from 17 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Revolution Medicines Inc is for a loss of $1.98 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Revolution Medicines Inc is $211.00, about 15.6% above its last closing price of $182.45
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.86
-1.84
-2.29
Missed
-24.5
Dec. 31 2026
-1.58
-1.58
-1.86
Missed
-17.7
Sep. 30 2025
-1.43
-1.42
-1.61
Missed
-13.5​
Jun. 30 2025
-1.14
-1.14
-1.31
Missed
-15
​​Mar. 31 2025
-1.11
-1.09
-1.13
Missed
-3.6
Dec. 31 2024
-0.98
-0.99
-1.12
Missed
-13.5​
Sep. 30 2024
-0.89
-0.89
-0.94
Missed
-5.2
Jun. 30 2024
-0.79
-0.77
-0.81
Missed
-4.5
This summary was machine generated August 3 at 23:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)